Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial
<strong>Background</strong> For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 d...
Main Author: | BREATHER (PENTA 16) Trial Group |
---|---|
Other Authors: | Inshaw, J |
Format: | Journal article |
Published: |
Elsevier
2016
|
Similar Items
-
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
by: Anna Turkova, et al.
Published: (2018-01-01) -
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial
by: Karina Butler, et al.
Published: (2016-06-01) -
‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
by: Gary Maartens
Published: (2020-01-01) -
Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017) -
Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
by: Innocent Lule Segamwenge, et al.
Published: (2018-01-01)